

Alaska Prescription Drug Monitoring Program Summary Prepared for the Board of Examiners in Optometry October 2020



This report contains high-level information on the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

Notices

- The Board of Pharmacy sent a letter to all licensees about mandatory PDMP registration and use in July.
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- The PDMP received two grants: the State Opioid Response grant, and a partial award of the Bureau of Justice Assistance grant.
- We will have our analysis of the spring survey at the end of the month and will be able to share at the next meeting.

Registration

Number of licensed Optometrists: 214

PDMP Optometry registrations in Portal: 46 (77 with DEA registration designation)

Number of Optometrists registered in AWARe: 73

Compliance rate (licensure and AWARe): 34%

Compliance rate (licensure and PDMP registrations): 21%

Compliance rate (license and DEA designations in AWARe): 95%




Figure 1. Cumulative registration of optometrists over a nearly 4-year period (33% change).

Use

Optometrists prescribing opioids from Q1 and Q2 (10/01/2019 – 06/30/2020): 5

Review compliance for Sched II – III (05/01/2020 – 10/31/2020), over a 3-day supply: 0%

Reporting

Unless excused from reporting under 17.30.200(u), daily reporting applies to you if:

- a. You are the PIC of a pharmacy dispensing federally scheduled II – IV controlled substances;
- OR**
- b. You are a practitioner who directly dispenses federally scheduled II – IV controlled substances

Alaska Prescription Drug Monitoring Program
Summary Prepared for the Board of Examiners in Optometry
October 2020



Top Medications Prescribed in Q1 and Q2:

1. hydrocodone bitartrate/acetaminophen (schedule III)
2. acetaminophen with codeine phosphate (schedule III)

Recommendations

- Providers should be notified they cannot prescribe federally scheduled II or III controlled substances until their account in AWA_{Rx}E has been approved
- Encourage increased compliance with registration and reviewing
- Educate providers on the use of delegates
- Provide guidance to licensees on prescribing practices
- Establish a disciplinary matrix to assist the board in determining appropriate disciplinary action for failure to comply with existing laws and regulations